Celldex Therapeutics CLDX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's accounts receivable?
- Celldex Therapeutics (CLDX) reported accounts receivable of $230K in Q1 2026.
- How has Celldex Therapeutics's accounts receivable changed year-over-year?
- Celldex Therapeutics's accounts receivable decreased by 78.4% year-over-year, from $1.06M to $230K.
- What is the long-term trend for Celldex Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accounts receivable has grown at a 2.3% compound annual growth rate (CAGR), from $1.8M to $2.02M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.